Please provide your email address to receive an email when new articles are posted on . The FDA approved ProAir RespiClick for the treatment of bronchospasm in patients aged 12 years and older with ...
Teva announced that the FDA has approved ProAir RespiClick (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in children aged 4-11 years with reversible obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback